Hyperliquid Strategies Announces $1 Billion Funding Push for Market Expansion

Hyperliquid Strategies, a pending merger between Nasdaq-listed Sonnet BioTherapeutics and special purpose acquisition firm (SPAC) Rorschach I LLC, has filed an S-1 statement with the US Securities and Exchange Commission (SEC). The company aims to raise up to $1 billion through a public offering, issuing up to 160 million shares of common stock. Chardan Capital Markets is serving as financial advisor for this fundraising effort.